Editas Medicine, Inc.

NASDAQ:EDIT

Biotechnology

Healthcare
$1.83 +2.65%

+$0.07 today

Market cap
$281.67M
Beta
2.10
P/E (TTM)
-2.4
EPS (TTM)
-$1.11
52W Low $1.66High $4.54

Volume 2.02M

Average 2.06M

Returns on capital

Editas Medicine, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-586.6%

avg -97.5%

ROIC

-65.6%

avg -42.2%

ROA

-85.8%

avg -41.2%

Analysis

ROIC is currently the strongest return metric at -65.6% versus its period average of -42.2%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Gilmore O'Neill

President, Chief Executive Officer & DirectorUSD 1.07M62——

Linda C. Burkly

Executive Vice President & Chief Scientific OfficerUSD 734.97K69——

Amy Parison

Senior Vice President & Chief Financial OfficerUSD 555.52K4013.84K0.01%

Feng Zhang

Co-Founder & Scientific Advisory Board Member——125.00K0.13%

George McDonald Church

Co-Founder & Scientific Advisory Board Member—72——

Damien Grierson

Senior Vice President, General Counsel & Corporate Secretary————

Frank Panaccio

Senior Vice President & Chief Business Officer————

Gregory Whitehead

Executive Vice President and Chief Technical & Quality Officer————

Tom Love

Vice President of People————

Brieana Buckley

Senior Vice President of Development and Program Leadership————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Sep 3, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

0

$0.00

Sells

16

$176,721.87

Net Transaction Value

−$176,721.87

Net selling

Most Active

Burkly Linda

6 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Nov 11, 26

O'Neill Gilmore Neil

Direct

Sell$51.1K
Nov 11, 26

Burkly Linda

Direct

Sell$18.9K
Sep 3, 26

Burkly Linda

Direct

Sell$2.2K
Sep 3, 26

Parison Amy

Direct

Sell$1.4K
Sep 3, 26

O'Neill Gilmore Neil

Direct

Sell$15.6K
Aug 3, 26

Parison Amy

Direct

Sell$1.7K
Jul 28, 26

Burkly Linda

Direct

Sell$13.2K
Jun 3, 26

Parison Amy

Direct

Sell$1.3K
Jun 3, 26

O'Neill Gilmore Neil

Direct

Sell$41.5K
Jun 3, 26

Burkly Linda

Direct

Sell$2K

1–10 of 16

Summary

Insiders reported 0 buys worth $0.00 and 16 sells worth $176,721.87 over the last 12 months. That adds up to net selling of $176,721.87. Burkly Linda was the most active insider with 6 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A2 analysts
RevenueN/AN/A+27.1%
-13.5% (5yr)5 analysts
Net IncomeN/AN/AN/A
N/A5 analysts
EBITN/AN/AN/A
N/A5 analysts

Analysis

Recent growth has been strongest in Revenue at +27.1% over three years. Forward estimates point to Revenue at -13.5% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Competitors

Who does Editas Medicine, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about EDIT's management, answered from reported figures.

Who manages EDIT?

Editas Medicine, Inc. (EDIT) lists 10 active executives. The top listed executive is Feng Zhang, Co-Founder & Scientific Advisory Board Member.

Are EDIT insiders buying or selling?

Recent insider activity shows net buying of $42.42M.